Cuure
Founded 2019 · 42 employees on LinkedIn · 2 known investors
Cuure offers personalized dietary supplements, recommending tailored wellness solutions based on individual needs and goals. Its formulas are developed with a scientific committee and R&D team, backed by clinical studies, and formulated and manufactured in France.
Also known as Groupe Well SAS
Founders & leadership
Cuure was founded in 2019 by Hugo Facchin and Jules Marcilhacy.

Investors · 2
Company profile
researched Aug 2026Cuure is a French company, operating under the legal entity Groupe Well SAS in Paris, that sells food supplements built around a personalisation model. Customers complete an online questionnaire covering lifestyle, goals and health needs, and receive a recommendation produced with the input of the company's Scientific Committee. The flagship offer, MyCuure, is a monthly box of 30 daily sachets grouping the recommended supplements into a single daily dose, delivered by subscription and adjustable over time. Alongside the personalised box, Cuure sells individual "Essentials" (vitamins, minerals, fatty acids, amino acids, adaptogenic plants) and three proprietary formulas: FS-3B, combining pre-, pro- and postbiotics with triple encapsulation for digestive comfort; MA-05, positioned as a metabolism activator; and Onely, an all-in-one powder said to gather 82 premium actives.
The company describes itself as a French laboratory founded in 2019 whose stated mission covers health solutions more broadly than supplements — including biological tests and tracking technologies. Products are formulated and manufactured in France, tested in independent or third-party laboratories, and registered with the French Directorate General for Food (DGAL). A mobile app supports adherence tracking, progress monitoring, order management and a loyalty programme. Its catalogue lists 79 products and 256 ingredients, spanning needs such as energy, stress, sleep, skin, immunity, digestion, joints, vision, sport, conception and maternity, and menopause.
Cuure's Scientific Committee includes researchers and clinicians such as Dafni Hadjieconomou (Paris Brain Institute – INSERM), Djihad Hadjadj (Université Paris Cité – Institut Cochin), nutrition doctor Armelle Marcilhacy, nutritionist Sabrina Lento, Florence Constant (MD, PhD in epidemiology and public health) and Silivia Faré (professor of bioengineering, Politecnico di Milano).
Founding story
Jules Marcilhacy and Hugo Facchin conceived the business in 2019 after seeing personalised supplement models succeed in the United States and questioning whether the approach could work in Europe. Marcilhacy, the son of a doctor and nutritionist, and Facchin both had e-commerce backgrounds; Facchin had earlier run a direct-to-consumer venture in the US and came from a family of entrepreneurs in health and wellness. Marcilhacy built a first prototype — homepage plus onboarding questionnaire delivering recommendations — over a single weekend on the no-code platform Bubble to test the acquisition funnel, then built the first version of the personalisation algorithm in a second weekend. The founders gave themselves three months to launch commercially and made their first sale, a 30-day subscription, within that window.
Business model
Direct-to-consumer e-commerce with a recurring subscription at its core: the MyCuure personalised box ships monthly as 30 daily sachets, while individual supplements are also sold as one-off or 30-day units (for example Vitamin D3 at €6.90 for 30 days, Multivitamins at €24.90, Morosil at €19.90). A loyalty programme rewards customers from their second order, and additional channels referenced include pharmacy access, an ambassador programme and referrals.
Revenue comes from product sales, primarily recurring monthly subscription boxes of personalised sachets, plus à la carte supplement purchases at unit prices; box-format items are priced at a discount to the list price (e.g. €6.21 vs €6.90 for Vitamin D3).
Traction
The company reports a community of more than 300,000 people and over 30,000 five-star product reviews; individual products show large review counts (2,721 for Vitamin D3, 2,561 for Omega 3, 2,277 for Probiotic Blend). It states 94% of customers see an improvement in overall wellbeing and 91% on their main need after three months, and cites 76 clinical and pre-clinical studies on its ingredients. Revenue grew to over €100,000 per month before the July 2020 seed round; the company reached $10M in total funding and 30+ employees, with a team of 25 (2 co-founders, 15 full-time, 3 interns, 5 freelancers) reported in an earlier founder interview.
Latest developments
As of 2023 the tech team had grown to ten people and was building a mobile app conceived as the entry point to a wider health and wellness experience, with a vision of surrounding the supplement range with on-demand access to experts, testing and other services. The current catalogue features three proprietary formulas — FS-3B, MA-05 and Onely — alongside the MyCuure personalised box and the Essentials range.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Cuure positions itself as a science-led French supplement laboratory and claims to be the global leader in personalised health; it draws on a Scientific Committee of academic and medical experts and cites clinical evidence as a differentiator.
Personalisation at the sachet level — a stated 1,800 billion possible combinations across 60+ products and 18 health needs — combined with an in-house Scientific Committee and R&D team, formulation and packing in France, full ingredient traceability, independent or third-party lab testing, 87% vegan products, and a continuous-analysis loop in which user data is collected and analysed to refine formulas and the recommendation engine.
Technology
A recommendation engine translates online questionnaire answers into a personalised supplement selection. The consumer-facing product was originally built on the no-code platform Bubble — prototype, personalisation algorithm and subscription engine — and Bubble remains central to a now-hybrid stack, also powering interfaces for the logistics centre that handles per-order personalisation and custom instruction printing. A mobile app provides reminders, progress tracking, loyalty and order management.
Go-to-market
Digital marketing and digital customer acquisition were used to reach the first 100 customers and remain the core strategy; the founders monitor CPA, LTV, AOV and repeat rate. Complementary channels listed on the site include a loyalty programme, referrals, an ambassador programme, pharmacy access and press/partnerships.
Consumers in Europe (B2C), addressed broadly rather than by narrow segment given the personalised approach; site messaging targets specific needs such as digestion, stress, sleep, immunity, skin, female comfort, male health, sport and weight management after 35.
Geography
Headquartered at 142 Rue Montmartre, 75002 Paris, France (Groupe Well SAS, RCS Paris B 849 602 917), with products formulated and manufactured in France (encapsulation for Vitamin D3 carried out in Spain with quality control in France) and sales across Europe; free EU delivery above a stated order threshold.
History
Founded in 2019 as a French laboratory. Six months after starting the project the founders raised an angel round, then hired a small team while deliberately not recruiting a CTO, since Marcilhacy handled product build himself while serving as co-founder and COO. Over the following year the company focused on operations, developing logistics-centre software to support per-order personalisation, including printing custom instructions for each order, with a Bubble-built interface allowing the team to update offers and site content in sync with the warehouse. A €1 million seed round followed in July 2020 and a €10 million Series A in September 2022. By 2023 the tech team numbered ten people and was working on a mobile app intended as the gateway to a broader health and wellness offering.
Risks & controversies
Marketing claims such as global leadership in personalised health and percentage improvement figures are company-reported. Regulatory framing is explicit on the site: supplements are registered with the DGAL and are not intended to diagnose, treat, cure or prevent disease, with medical advice recommended for people who are ill, pregnant or breastfeeding. The founder has noted that operating as an entrepreneur in France is harder than in the US.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsCuure raised a €10 million Series A, roughly two years after its seed round.
Cuure raised a €1 million seed round after monthly revenue grew to over €100,000.
Six months after starting work on the project, the founders raised a round of funding from angel investors.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Cuurecuure.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Cuure do?
- French lab selling science-backed personalised food supplements by monthly subscription, founded in 2019.
- Who founded Cuure?
- Cuure was founded by Hugo Facchin, Jules Marcilhacy in 2019.
- Who are Cuure's investors?
- Cuure's investors include JamJar Investments, V3 Ventures.
